Practicing since 1990

Your dental needs are our greatest concern. Life is busy so we make every effort to see our patients on time. We are also proud of our office with its modern equipment. Please feel free to come by and have a tour to see for yourself.

 

Woman's face showing before and after with Botox


Woman's face showing before and after with Botox


Woman's face showing before and after with Botox


Man's face showing before and after with Botox

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information
Indications
BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the
appearance of:
- moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- moderate to severe lateral canthal lines associated with orbicularis oculi activity
- moderate to severe forehead lines associated with frontalis activity
IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports indicate that the effects of BOTOX®
Cosmetic and all botulinum toxin
products may spread from the area of injection to produce symptoms consistent with botulinum
toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis,
dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms
have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life
threatening and there have been reports of death. The risk of symptoms is probably greatest in
children treated for spasticity but symptoms can also occur in adults treated for spasticity and other
conditions, particularly in those patients who have an underlying condition that would predispose
them to these symptoms. In unapproved uses, including spasticity in children, and in approved
indications, cases of spread of effect have been reported at doses comparable to those used to
treat cervical dystonia and spasticity and at lower doses.
CONTRAINDICATIONS
BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in
individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the
formulation.
WARNINGS AND PRECAUTIONS
Lack of Interchangeability between Botulinum Toxin Products
The potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized.
They are not interchangeable with other preparations of botulinum toxin products and, therefore,
units of biological activity of BOTOX®
Cosmetic cannot be compared to nor converted into units of
any other botulinum toxin products assessed with any other specific assay method.
Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use
of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines),
40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines
and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and
forehead lines) have been reported.
Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some
adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX®
injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant
spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or
adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant
disabilities. There is insufficient information to identify factors associated with an increased risk for adverse
reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for
unapproved uses have not been established.
Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported. These reactions include
anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further
injection of BOTOX®
Cosmetic should be discontinued and appropriate medical therapy immediately
instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and,
consequently, the causal agent cannot be reliably determined.
Cardiovascular System
There have been reports following administration of BOTOX®
of adverse events involving the cardiovascular
system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients
had risk factors including pre-existing cardiovascular disease. Use caution when administering to patients
with pre-existing cardiovascular disease.
Increased Risk of Clinically Significant Effects with Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular
junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given
botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant
effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia,
and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions).
Dysphagia and Breathing Difficulties
Treatment with BOTOX®
and other botulinum toxin products can result in swallowing or breathing difficulties.
Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these
complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are
involved in breathing or oropharyngeal muscles that control swallowing or breathing (see Boxed Warning).
Pre-existing Conditions at the Injection Site
Caution should be used when BOTOX®
Cosmetic treatment is used in the presence of inflammation at the
proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).
Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on effective donor screening and product
manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant
Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease
(CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No
cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or
albumin contained in other licensed products.
ADVERSE REACTIONS
The most frequently reported adverse reaction following injection of BOTOX®
Cosmetic for glabellar lines
was eyelid ptosis (3%).
The most frequently reported adverse reaction following injection of BOTOX®
Cosmetic for lateral canthal
lines was eyelid edema (1%).
The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines
with glabellar lines were headache (9%), brow ptosis (2%) and eyelid ptosis (2%).
DRUG INTERACTIONS
Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular
transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin
may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate
systemic anticholinergic effects.
The effect of administering different botulinum neurotoxin products at the same time or within several
months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by
administration of another botulinum toxin prior to the resolution of the effects of a previously administered
botulinum toxin.
Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after
administration of BOTOX® Cosmetic.
USE IN SPECIFIC POPULATIONS
There are no studies or adequate data from postmarketing surveillance on the developmental risk
associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of
BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk
production.
[Insert appropriate PI statement]
For more information on BOTOX® Cosmetic, please see the accompanying full Prescribing
Information including Boxed Warning and Medication Guide. (or other appropriate
statement)
Please see BOTOX® Cosmetic Full Prescribing Information including Boxed Warning and
Medication Guide.
BCT110283 10/17
292 Hancock Square
Bay St. Louis, MS 39520
228-467-4670
Hours: Mon-Thurs 8-5, Closed Fri & Sat